ESR1 and cancer: However, the anti-estrogen agents prevent both translocation and nuclear binding of the receptor, thereby blocking ER, resulting in the inhibition of transcriptional activation of estrogen-responsive genes; they also possess potential disease-stabilizing effects in other cancer types 41, 84.